Life Sciences

  • May 01, 2026

    Biotech IPOs Surge Ahead As 2 Listings Raise $557M

    A pair of biotechnology firms began trading on Friday after raising a combined $557 million through upsized initial public offerings that both priced at the top of their proposed $16 to $18 ranges, marking the latest drug developers to join the IPO market in recent weeks.

  • May 01, 2026

    5th Circ. Pauses Mail-Order Access To Abortion Pills

    The Fifth Circuit on Friday reinstated an in-person dispensing requirement for the abortion medication mifepristone, blocking mail-order access while a challenge to a Biden administration regulation brought by Louisiana officials moves forward.

  • May 01, 2026

    Pharma Co. Investor Sues Over Misleading Aurinia Deal

    A Kezar Life Sciences investor has filed suit asking an Illinois federal judge to halt the company's planned acquisition by a Canadian biopharmaceutical company's U.S. unit unless Kezar fixes the "incomplete and misleading" regulatory filings it submitted regarding the transaction.

  • May 01, 2026

    Biotech Firm Wants Do-Over After Consultant's $58M Verdict

    A Georgia-based medical technology firm that was hit with a $58 million verdict last month over claims that it conspired to have a former consultant arrested has asked a Fulton County judge for a new trial, arguing the court allowed a jury charge that was "erroneous, irrelevant, [and] not tailored to the evidence."

  • May 01, 2026

    Vietnam Tops USTR Priority IP Watch List In Latest Report

    Vietnam hasn't dealt with "long-standing" issues to protect and enforce intellectual property rights, and its actions have had the biggest negative impact on U.S. products, according to the Office of the U.S. Trade Representative's latest annual global IP report.

  • May 01, 2026

    How Paul Clement Does It All

    For most lawyers, getting to argue before the U.S. Supreme Court is a once-in-a-lifetime event, but for a select few, it's a common occurrence. Clement & Murphy PLLC name partner Paul Clement is one of those lawyers. 

  • May 01, 2026

    Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion

    Biopharmaceutical company Esperion Therapeutics, advised by Goodwin Procter LLP, on Friday announced plans to go private after being bought by Sidley Austin LLP-led healthcare-focused investment firm Archimed in a $1.1 billion deal.

  • May 01, 2026

    Mylan Inks $11M Deal With NC Over EpiPen Pricing

    North Carolina Attorney General Jeff Jackson announced Thursday that the state has inked an $11 million settlement with EpiPen distributor Mylan Pharmaceuticals, resolving claims of anticompetitive conduct and funneling millions back into public healthcare programs.

  • April 30, 2026

    Medtronic User Says Data Hack Exposed 9M Client Records

    A Medtronic customer filed a proposed class action Thursday accusing the medical device company of failing to safeguard more than 9 million records containing personally identifiable information — including health information — exposed in a data breach earlier this month.

  • April 30, 2026

    Acadia Investors Get Final OK For $179M Deal, Atty Fees

    A Tennessee federal judge has given final approval to a $179 million settlement between investors and Acadia Healthcare Co. Inc., ending a class action that alleged the company misled investors about the strength of its U.K. operations.

  • April 30, 2026

    Jury Begins Mulling If Doctors Are Liable For Fatal Overdose

    A Philadelphia jury on Thursday began deliberations in a lawsuit accusing two doctors of enabling a 26-year-old man with chronic back pain to become hooked on opioid painkillers and fatally overdose.

  • April 30, 2026

    Trump Taps 3rd Surgeon General Pick, Drops Casey Means

    President Donald Trump nominated his third pick to be surgeon general on Thursday, withdrawing consideration for Casey Means after her confirmation stalled in the Senate. 

  • April 30, 2026

    Crypto Co. Fights Shkreli's Counterclaims In Album Case

    A cryptocurrency company suing "Pharma Bro" Martin Shkreli over ownership of a coveted Wu-Tang Clan album has asked a Brooklyn federal judge to dismiss his counterclaims, calling his claim seeking a declaration that he didn't steal trade secrets related to the album a "mirror image" of the company's claim saying he did.

  • April 30, 2026

    Supplement Industry Says FDA Wrongly Muzzled Label Claims

    A coalition of dietary supplement companies and an alternative medicine advocacy group filed suit Wednesday against the U.S. Food and Drug Administration, claiming that the agency violated First Amendment commercial speech protections when it blocked product label claims connecting certain nutrients or ingredients to health outcomes.

  • April 30, 2026

    Critical Mineral Restrictions Up 500% From 2009, OECD Says

    Global export restrictions on critical raw materials that are key for digital and renewable energy technologies increased fivefold between 2009 and 2024, which could lead to greater risks of supply chain vulnerabilities, the Organization for Economic Cooperation and Development said.

  • April 30, 2026

    NJ University Can't Escape Ex-Professor's Age Bias Suit

    A New Jersey university must face a former professor's lawsuit claiming she was demoted because she was in her 60s and fired after she complained, as a federal judge ruled her allegations were detailed enough to stay in court.

  • April 30, 2026

    Goodwin, Davis Polk Lead Avalyn's Upsized $300M IPO

    Biotechnology firm Avalyn Pharma Inc. began trading publicly Thursday after raising $300 million in an upsized initial public offering.

  • April 30, 2026

    NC Biz Court Bulletin: Corporate Raid, MV Realty Settlement

    A major case settled in the North Carolina Business Court in April as new lawsuits emerged, including a complaint by health information technology company IQVIA Holdings Inc. accusing its former top brass of orchestrating a corporate raid and defecting to a competitor. In case you missed this story and others, here are the highlights.

  • April 30, 2026

    J&J Says Ill. Ruling Backs Beasley Allen's DQ From Talc Suits

    Johnson & Johnson told a New Jersey federal court that a recent ruling in Illinois backs the Beasley Allen Law Firm's disqualification from multidistrict litigation over its talcum powder.

  • April 30, 2026

    Purdue's $125M McKinsey Deal Gets OK Ahead Of Ch. 11 Exit

    Purdue Pharma LP on Thursday secured a New York bankruptcy judge's approval of a $125 million agreement with McKinsey & Co. that settles claims tied to the consulting firm's work advising Purdue on the sale and marketing of opioids, clearing the way for the pharmaceutical company to exit Chapter 11 and put its $7.4 billion bankruptcy plan into effect.

  • April 30, 2026

    Express Scripts, Cigna Seek End To Ohio PBM Price Suit

    After the Sixth Circuit ruled that a legal dispute between Ohio and a group of pharmacy benefit managers belongs in federal court, Express Scripts and Cigna now want dismissed the lawsuit accusing them of participating in an antitrust conspiracy that is driving up prescription drug prices. 

  • April 30, 2026

    Kratom Seller Sanctioned For Deleting Blog During Suit

    A California federal judge has sanctioned Ashlynn Marketing Group Inc. in a suit alleging it hid kratom's dangerous and addictive effects, finding that it deliberately deleted a blog containing statements about kratom after the suit was filed.

  • April 29, 2026

    J&J, Neutrogena Say FDA Signed Off On Benzene Products

    Johnson & Johnson Consumer Inc. and Kenvue Inc. are calling for a permanent end to a multistate consumer lawsuit claiming their Clean & Clear and Neutrogena acne treatments degrade into the cancer-causing chemical benzene, arguing in New Jersey federal court that federal regulators have already determined that the key ingredient is safe.

  • April 29, 2026

    Feds Say Lack Of Injury Dooms Gold Card Program Challenge

    The Trump administration said a suit challenging the gold card visa program's legality must be thrown out because the immigrants and academic professionals union that filed it can't show the program hurts their chances at getting visas.

  • April 29, 2026

    High Court Seeks Path To Limited Ruling On 'Skinny Labels'

    The U.S. Supreme Court on Wednesday appeared reluctant to craft new standards for deciding whether makers of generic drugs that use so-called skinny labels have encouraged others to infringe patents, with several justices saying existing law is sufficient to make a decision.

Expert Analysis

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.